血液透析发生结核感染的影响因素分析

目的分析维持性血液透析患者发生结核感染的影响因素及临床特点。方法回顾性调查2018年5月-2019年8月北京清华长庚医院肾内科收治的长期规律血液透析患者共150例,收集患者的年龄、性别、合并疾病、血常规、生化、透析充分性等检验结果和影像学资料,归纳分析血液透析患者发生结核感染的影响因素。结果150例血液透析患者,男性91人,女性59人,平均年龄(62.7±14.2)岁,发生结核感染者共11例(7.33%),其中肺外结核比例高(54.5%),以浆膜腔积液为主要表现(54.5%),血红蛋白(94.7±11.6)g/L、血清白蛋白(34.6±2.0)g/L、血肌酐(593.6±221.4)umol/L低于无结核感染者,差异具有统计学意义(P<0.05);血小板(228.7±103.5)×10⁹/L高于无结核感染者,差异具有统计学意义(P<0.05)。两组患者年龄、透析充分性、淋巴细胞、血糖、血脂、血钙、血磷、全段甲状旁腺激素无统计学差异。结论血红蛋白<110g/L、白蛋白<35g/L是MHD患者发生结核感染的高危因素,MHD患者发生结核感染以肺外结核为主,临床表现具有隐匿性和不典型性,临床工作应提高警惕避免漏诊。     

Paediatric pulmonary actinomycosis: A forgotten disease

Actinomycosis is a rare, indolent and invasive infection caused by Actinomyces species. Actinomycosis develops when there is disruption of the mucosal barrier, and invasion and systemic spread of the organism, which can lead to endogenous infection affecting numerous organs. It is known to spread in tissue through fascial planes and most often involves the cervicofacial (55%), abdominopelvic (20%) and thoracic (15%) soft tissue. Pulmonary actinomycosis is rare in patients under the age of five years, with the median reported age in the fifth decade. Clinical findings include chest wall mass (49%), cough (40%), pain (back, chest, shoulders) (36%), weight loss (19%), fever (19%), Draining sinuses (15%) and hemoptysis (9%). Chest x-ray findings in pulmonary actinomycosis are mostly nonspecific and can overlap with pulmonary tuberculosis, foreign body aspiration and malignancy. Endobronchial tissue aggregates may show sulphur granules, with yellow to white conglomerate areas of gram positive Actinomyces. Removal or biopsy of these large endobronchial masses must be done with care, because of the risk of bleeding and large airway obstruction. The cytology on bronchoalveolar lavage fluid may show Periodic acid–Schiff (PAS) positive stain, ZN negative and Gram-positive filamentous bacilli which is morphologically suggestive of Actinomycosis. Actinomyces spp is highly susceptible to beta lactam antibiotics, penicillin G, and amoxicillin. A minimum of 3–6 months is needed but up to 20 months of treatment may be needed. Early diagnosis and correct treatment can lead to a good prognosis with a low mortality.     

Association of vitamin D levels and risk of latent tuberculosis in the hemodialysis population

BackgroundVitamin D is essential in the host defense against tuberculosis (TB). Suboptimal vitamin D status is common in the hemodialysis population. Hemodialysis patients have an increased risk compared to the general population latent tuberculosis infection (LTBI). However, the association between vitamin D deficiency and LTBI in this population remains unclear.Materials and methodsWe conducted a cross-sectional study between March and May 2017. Interferon-gamma release assay (IGRA) through QuantiFERON-TB Gold In-Tube was used to assess LTBI. Plasma 25-hydroxycholecalciferol (25-OHD) levels were measured by Elecsys Vitamin D Total assay. Suboptimal vitamin D levels included vitamin D insufficiency 20–29 ng/mg and vitamin D deficiency <20 ng/mL. Predictors for LTBI were analyzed.ResultsA total of 287 participants were enrolled. The suboptimal vitamin D level was 31.4% (90/287), which including the vitamin D deficiency was 13.9% (40/287). A total of 49.1% (141/287) people received nutritional vitamin D supplementation. The prevalence of IGRA positivity in this study was 25.1% (72/287). There was no significant difference in vitamin D concentrations or the proportion of vitamin D supplementation among the IGRA-positive and IGRA-negative groups (p = 0.789 and 0.496, respectively). In multivariate analysis, age >65 years old (odds ratio (OR), 1.89; 95% CI, 1.08–3.31; p = 0.026) and TB history (OR, 3.51; 95% CI, 1.38–8.91; p = 0.008) were independent predictors of IGRA positivity.ConclusionThis is the first study to report that vitamin D deficiency was not associated with IGRA positivity in a hemodialysis population. Aging and TB history were both independent predictors for LTBI.     

结核病与糖尿病共病的治疗管理专家共识

结核病与糖尿病均是临床上的常见病和多发病,两者可合并存在,相互影响。活动性结核病作为感染因素可加重糖尿病病情,而糖尿病患者又是发生结核病的高危人群,结核病与糖尿病双重负担将成为重大的全球公共卫生问题。因此,需重视结核病与糖尿病共病的治疗管理。本共识重点介绍了结核病与糖尿病共病的危害、发病机制、双向筛查、临床特点、诊断、治疗和管理等内容。     

正念行为护理对肺癌合并肺结核患者的护理效果观察

目的探讨正念行为护理对肺癌合并肺结核患者的护理效果。方法选取2019年1月至2020年1月间陕西省结核病防治院收治的97例肺癌合并肺结核患者,采用随机数表法分为对照组和观察组。对照组49例患者采用亲情护理,观察组48例患者采用正念行为护理。比较两组患者的屈服、回避和面对评分、自我效能感量表(GSES)、抑郁自评量表(SDS)和焦虑自评量表(SAS)评分及生活质量。结果护理后,两组患者的屈服、回避、SDS和SAS评分均较护理前降低,且观察组均低于对照组,差异均有统计学意义(均P<0.05)。护理后,两组患者的面对、GSES、情绪功能、社会功能、认知功能、躯体功能和角色功能评分均较护理前升高,且观察组均高于对照组,差异均有统计学意义(均P<0.05)。结论正念行为护理能促进肺癌合并肺结核患者养成积极的应对方式,提高自我效能,减轻不良情绪,提高生活质量,值得推广。     

Tuberculous osteomyelitis of tibial diaphysis following saphenous vein graft harvest for coronary artery bypass: a case report

Tuberculosis in the tibial diaphysis following saphenous vein graft harvest for coronary artery bypass grafting has not been reported, to the best of authors’ knowledge. We report the first such clinical case in view of its clinical rarity and as a complication of the simple procedure like saphenous vein graft harvest.     

结核性脑膜炎临床诊断评分体系的建立及评价研究

背景 结核性脑膜炎（TM）是临床常见的中枢性感染的一种，其起病较慢，症状不典型，病原学诊断困难，误诊率高。目前有效的TM诊断工具较少。利用常见的临床症状、检查指标等建立诊断评分系体可提高诊断准确率，减少误诊。 目的 建立TM临床诊断评分体系（TMCDS），并对其应用价值进行初步评价。 方法 选取2011年11月至2021年9月在柳州市人民医院感染病科住院并诊断为脑膜炎的患者187例为研究对象，采用SPSS 21.0统计软件将患者随机分成建模组（147例）和验模组（40例）。根据是否为TM将建模组分为非TM亚组（76例）和TM亚组（71例）。收集患者的一般资料，主要包括性别、年龄、临床症状（发热、头痛、意识障碍、颈抵抗），实验室及影像学检查结果，包括人类免疫缺陷病毒（HIV）感染情况、CD4+ T淋巴细胞计数、C反应蛋白、颅内压、脑脊液常规生化检查（糖、氯、蛋白、细胞数）。建模组采用多因素Logistic回归分析探讨TM的影响因素；根据每个因素的β值所占比重设立相应分值，建立TMCDS；采用受试者工作特征曲线（ROC曲线）分析TMCDS诊断TM的价值。 结果 两亚组头痛、HIV感染、CD4+ T淋巴细胞计数<200/μl、C反应蛋白升高、颅内压>200 mm H2O（1 mm H2O=0.009 8 kPa）、脑脊液糖降低、脑脊液氯降低、脑脊液蛋白升高、脑脊液单核细胞升高情况比较，差异有统计学意义（P<0.05）。多因素Logistic回归分析结果显示，头痛、CD4+ T淋巴细胞<200/μl、C反应蛋白升高、脑脊液糖降低、脑脊液蛋白升高均是TM的影响因素（P<0.05）。将以上5个影响因素同时结合临床经验纳入脑脊液氯、脑脊液细胞数再次进行多因素Logistic回归分析，结果显示，头痛、CD4+ T淋巴细胞<200/μl、C反应蛋白升高、脑脊液糖降低、脑脊液蛋白升高均是TM的影响因素（P<0.05）。根据上述7个因素β值建立评分系统，将脑脊液氯降低β值设定为1分，其他因素β值与其的倍数即为该因素所对应的分值，因2个影响因素评分为负值，为方便临床，每个因素对应分值增加2.5分，最终建立TMCDS。TMCDS诊断建模组TM的ROC曲线下面积（AUC）为0.807〔95%CI（0.735，0.879），标准误=0.037，P<0.001〕，最佳诊断界值为21.50分。TMCDS诊断验模组TM的AUC为0.766〔95%CI（0.610，0.921），标准误=0.079，P=0.004〕，灵敏度为0.789，特异度为0.667。 结论 通过7个变量建立的TMCDS简单易行，对于早期TM具有较高的临床诊断价值。     

Comparison of eight Lactobacillus species for delivery of surface-displayed mycobacterial antigen

Lactobacillus spp. comprise a large group of Gram-positive lactic acid bacteria with varying physiological, ecological and immunomodulatory properties that are widely exploited by mankind, primarily in food production and as health-promoting probiotics. Recent years have shown increased interest in using lactobacilli for delivery of vaccines, mainly due to their ability to skew the immune system towards pro-inflammatory responses. We have compared the potential of eight Lactobacillus species, L. plantarum, L. brevis, L. curvatus, L. rhamnosus, L. sakei, L. gasseri, L. acidophilus and L. reuteri, as immunogenic carriers of the Ag85B-ESAT-6 antigen from Mycobacterium tuberculosis. Surface-display of the antigen was achieved in L. plantarum, L. brevis, L. gasseri and L. reuteri and these strains were further analyzed in terms of their in vitro and in vivo immunogenicity. All strains activated human dendritic cells in vitro. Immunization of mice using a homologous prime-boost regimen comprising a primary subcutaneous immunization followed by three intranasal boosters, led to slightly elevated IgG levels in serum in most strains, and, importantly, to significantly increased levels of antigen-specific mucosal IgA. Cellular immunity was assessed by studying antigen-specific T cell responses in splenocytes, which did not reveal proliferation as assessed by the expression of Ki67, but which showed clear antigen-specific IFN-γ and IL-17 responses for some of the groups. Taken together, the present results indicate that L. plantarum and L. brevis are the most promising carriers of TB vaccines.     

Novel vaccination strategies and approaches against human tuberculosis

Tuberculosis (TB) remains one of a major health problem worldwide. Tuberculosis vaccine research has made an extraordinary progress over the past few years. However, there is still no replacement for the Bacillus Calmette‐Guérin vaccine, the only TB vaccine licensed for human use. Therefore, the discovery and development of new TB vaccines remains a priority. This article discusses current strategies used to diversify TB vaccines and includes discussion of the status of efforts to improve protection against Mycobacterium tuberculosis (M tb) infection or TB disease by developing new and safe TB vaccines. This article also highlights the current research efforts in immune‐enhancing approaches to improve vaccination efficacy. The development of more effective TB vaccines might have significant impact on global TB control.